| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
98,530,000 |
| Market
Cap: |
18.88(M) |
| Last
Volume: |
78,874 |
Avg
Vol: |
78,661 |
| 52
Week Range: |
$0.1916 - $0.1916 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Co.'s primary clinical program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, which is in the pivotal Phase 3 VIITAL™ clinical trial. Co. is developing additional adeno-associated virus (AAV)-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM™ capsid platform that Co. has licensed from University of North Carolina at Chapel Hill, and internal AAV vector research programs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
42,758 |
62,758 |
88,758 |
104,627 |
| Total Buy Value |
$154,036 |
$241,836 |
$346,094 |
$404,389 |
| Total People Bought |
5 |
5 |
5 |
5 |
| Total Buy Transactions |
5 |
6 |
9 |
12 |
| Total Shares Sold |
0 |
7,084 |
41,479 |
43,636 |
| Total Sell Value |
$0 |
$36,199 |
$179,159 |
$185,051 |
| Total People Sold |
0 |
1 |
5 |
5 |
| Total Sell Transactions |
0 |
1 |
8 |
11 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Omalley Brendan M. |
SVP, General Counsel |
• – – |
2021-10-05 |
4 |
AS |
$1.05 |
$2,569 |
D/D |
(2,447) |
271,007 |
|
-72% |
|
| Amoroso Michael |
Chief Executive Officer |
• • – |
2021-09-30 |
4 |
AS |
$1.09 |
$49,382 |
D/D |
(45,409) |
604,637 |
|
-76% |
|
| Omalley Brendan M. |
SVP, General CounselOfficer |
• – – |
2021-09-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
137,454 |
|
-79% |
|
| Omalley Brendan M. |
SVP, General Counsel |
• – – |
2021-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
136,000 |
273,454 |
|
- |
|
| Carr Edward |
Chief Financial Officer |
• – – |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
238,000 |
429,291 |
|
- |
|
| Seshadri Vishwas |
SVP, Head of Res./Clin. Dev. |
• – – |
2021-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
| Mann Paul Elliot |
Director |
– • – |
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
38,590 |
38,590 |
|
- |
|
| Wider Todd |
Director |
– • – |
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
38,590 |
63,590 |
|
- |
|
| Charles Faith L. |
Director |
– • – |
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
77,181 |
77,181 |
|
- |
|
| Alland Leila |
Director |
– • – |
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
77,181 |
77,181 |
|
- |
|
| Rouhandeh Steven H |
Director |
– • • |
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
38,590 |
533,590 |
|
- |
|
| Alvino Mark |
Director |
– • – |
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
77,181 |
82,181 |
|
- |
|
| Wuchterl Donald A. |
Director |
– • – |
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
77,181 |
77,181 |
|
- |
|
| Silverstein Christine Berni |
Director |
– • – |
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
38,590 |
118,590 |
|
- |
|
| Rouhandeh Steven H |
Director |
– • • |
2021-05-03 |
4 |
AS |
$2.01 |
$160,888 |
I/I |
(80,000) |
11,079,292 |
|
-36% |
|
| Amoroso Michael |
Chief Executive Officer |
• • – |
2021-03-31 |
4 |
AS |
$1.87 |
$84,919 |
D/D |
(45,409) |
650,046 |
|
-33% |
|
| Amoroso Michael |
Chief Executive Officer |
• • – |
2021-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
695,455 |
|
- |
|
| Rouhandeh Steven H |
Director |
– • • |
2021-03-18 |
4 |
AS |
$2.23 |
$178,624 |
I/I |
(80,000) |
11,159,292 |
|
-40% |
|
| Carr Edward |
Chief Accounting Officer |
• – – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
246,736 |
|
- |
|
| Amoroso Michael |
Chief Operating Officer |
• – – |
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
445,455 |
|
- |
|
| Mann Paul Elliot |
Director |
– • – |
2021-02-19 |
4 |
S |
$2.38 |
$108,502 |
D/D |
(45,566) |
0 |
|
35% |
|
| Mann Paul Elliot |
Director |
– • – |
2021-02-19 |
4 |
OE |
$1.28 |
$58,324 |
D/D |
45,566 |
45,566 |
|
- |
|
| Wider Todd |
Director |
– • – |
2021-02-19 |
4 |
S |
$2.39 |
$601,057 |
D/D |
(251,625) |
25,000 |
|
35% |
|
| Wider Todd |
Director |
– • – |
2021-02-18 |
4 |
S |
$2.43 |
$3,273 |
D/D |
(1,345) |
276,625 |
|
33% |
|
| Wider Todd |
Director |
– • – |
2021-02-18 |
4 |
OE |
$1.28 |
$1,722 |
D/D |
1,345 |
277,970 |
|
- |
|
211 Records found
|
|
Page 4 of 9 |
|
|
